Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name CC-122
Synonyms
Therapy Description

Avadomide (CC-122) is an immunomodulatory drug analog that targets Cereblon and promotes degradation of several proteins, including Ikaros and Aiolos, leading to decreased B-cell proliferation and decreased tumor angiogenesis (Blood Dec 2014, 124 (21) 3500).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
CC-122 Avadomide Avadomide (CC-122) is an immunomodulatory drug analog that targets Cereblon and promotes degradation of several proteins, including Ikaros and Aiolos, leading to decreased B-cell proliferation and decreased tumor angiogenesis (Blood Dec 2014, 124 (21) 3500).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown hematologic cancer not applicable CC-122 Phase I Actionable In a Phase I trial, Avadomide (CC-122) treatment was well tolerated in patients with hematological malignancies (n=7) and resulted in an objective response in 60% (3/5) of patients with non-Hodgkin's lymphoma, including a complete response in a patient with follicular lymphoma and a partial response in patients with follicular lymphoma and mantle cell lymphoma lasting more than 234 days, and stable disease in one patient with multiple myeloma lasting 932 days (PMID: 30201761; NCT01421524). 30201761
Unknown unknown central nervous system cancer not applicable CC-122 Phase I Actionable In a Phase I trial, Avadomide (CC-122) treatment was well tolerated in patients with central nervous system tumors, and resulted in a 6-month progression-free survival (PFS) rate of 83% (5/6) and a PFS ranging from 58 to 1,079 days (PMID: 30201761; NCT01421524). 30201761
Unknown unknown central nervous system cancer not applicable CC-122 Phase I Actionable In a Phase I trial, CC-122 demonstrated safety and preliminary efficacy in patients with glioblastom and other central nervous system tumors, resulted in a meidan progressin-free survival of 58 days (Neuro Oncol (2016) 18 (suppl 6): vi24.). detail...
Unknown unknown Advanced Solid Tumor not applicable CC-122 Phase I Actionable In a Phase I trial, Avadomide (CC-122) treatment was well tolerated in patients with advanced solid tumors (n=27) but did not result in any objective responses in patients with advanced solid tumors other than brain cancer (n=19), stable disease was observed in 2 patients (lasting 114 and 309 days) with hepatocellular carcinoma (PMID: 30201761; NCT01421524). 30201761

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status
NCT02406742 Phase Ib/II Obinutuzumab Rituximab Ibrutinib CC-122 A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL (ENHANCE) Active, not recruiting
NCT01421524 Phase I CC-122 Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Active, not recruiting


Additional content available in CKB BOOST